

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-12 (cancelled)

Claim 13 (currently amended): A method of treating tissue ~~fibrosis~~ fibrosis in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a composition comprising (a) ~~a molecule selected from the group consisting of an IL-13 antagonist and an IL-4 antagonist~~ an antibody to IL-13 or an IL-13 binding fragment of an antibody to IL-13; and (b) a pharmaceutically acceptable carrier, thereby treating tissue fibrosis in said subject.

Claims 14-15 (cancelled)

Claim 16 (original) The method of claim 13, wherein tissue fibrosis affects a tissue selected from the group consisting of liver, skin epidermis, skin endodermis, muscle, tendon, cartilage, cardiac tissue, pancreatic tissue, lung tissue, uterine tissue, neural tissue, testis, ovary, adrenal gland, artery vein, colon, small intestine biliary tract and gut.

Claim 17 (original) The method of claim 16 wherein said tissue is liver.

Claim 18 (original) The method of claim 17 wherein said fibrosis is that resulting from infection with schistosoma.

Claim 19 (original) The method of claim 13 wherein said fibrosis is that resulting from healing of a wound.

Claim 20 (original) The method of claim 13 wherein said wound is a surgical incision.

Claim 21 (currently amended): A method of inhibiting formation of tissue ~~fibrosis~~ fibrosis in a mammalian subject, said method comprising administering to said subject a therapeutically effective amount of a composition comprising (a) ~~a molecule selected from the~~

Applicants: Wynn et al.  
U.S.S.N. Not yet assigned

~~group consisting of an IL-13 antagonist and an IL-4 antagonist~~ an antibody to IL-13 or an IL-13 binding fragment of and IL-13 antibody; and (b) a pharmaceutically acceptable carrier, thereby inhibiting formation of tissue fibrosis in said subject.

Claims 22-23 (cancelled)

Claim 24 (original): The method of claim 21 wherein tissue fibrosis affects a tissue selected from the group consisting of liver, skin epidermis, skin endodermis, muscle, tendon, cartilage, cardiac tissue, pancreatic tissue, lung tissue, uterine tissue, neural tissue, testis, ovary, adrenal gland, artery vein, colon, small intestine biliary tract and gut.

Claim 25 (original): The method of claim 21 wherein said tissue is liver.

Claim 26 (original) The method of claim 25 wherein said fibrosis is that resulting from infection with schistosoma.

Claim 27 (original) The method of claim 21 wherein said fibrosis is that resulting from healing of a wound.

Claim 28 (original) The method of claim 27 wherein said wound is a surgical incision.

Claims 29-30 (cancelled)

Claim 31 (new): The method of claim 13, wherein said composition comprises an antibody to IL-13.

Claim 32 (new): The method of claim 13, wherein said composition comprises an IL-13 binding fragment of an antibody to IL-13.

Claim 33 (new): The method of claim 13, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

Claim 34 (new): The method of claim 31, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

Claim 35 (new): The method of claim 32, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

Claim 36 (new): The method of claim 13, wherein said composition is administered by intravenous, cutaneous, subcutaneous, or intravenous injection.

Claim 37 (new): The method of claim 13, wherein said composition is administered by intravenous injection.

Claim 38 (new): The method of claim 34, wherein said antibody is administered for about 12 to 24 hours of continuous administration.

Claim 39 (new): The method of claim 13, wherein said composition is administered at a dose of about 0.1  $\mu$ g to about 100 mg per kg body weight.

Claim 40 (new): The method of claim 13, wherein said composition is administered at a dose of about 20  $\mu$ g to about 500  $\mu$ g per kg body weight.

Claim 41 (new): The method of claim 21, wherein said composition comprises an antibody to IL-13.

Claim 42 (new): The method of claim 21, wherein said composition comprises an IL-13 binding fragment of an antibody to IL-13.

Claim 43 (new): The method of claim 21, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

Claim 44 (new): The method of claim 41, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

Claim 45 (new): The method of claim 42, wherein said antibody antagonizes binding of IL-13 to a human IL-13bc.

Claim 46 (new): The method of claim 21, wherein said composition is administered by intravenous, cutaneous, subcutaneous, or intravenous injection.

Claim 47 (new): The method of claim 21, wherein said composition is administered by intravenous injection.

Claim 48 (new): The method of claim 47, wherein said antibody is administered for about 12 to 24 hours of continuous administration.

Claim 49 (new): The method of claim 41, wherein said composition is administered at a dose of about 0.1  $\mu\text{g}$  to about 100 mg per kg body weight.

Claim 50 (new): The method of claim 41, wherein said composition is administered at a dose of about 20  $\mu\text{g}$  to about 500  $\mu\text{g}$  per kg body weight.